Corcept Therapeutics (NASDAQ: CORT) CDO sells 20,000 shares via 10b5-1 plan

Rhea-AI Filing Summary

Corcept Therapeutics Chief Development Officer William Guyer reported option exercises and share sales in company stock. On January 6, 2026, he exercised a stock option for 20,000 shares of common stock at an exercise price of $21.65 per share and then sold 20,000 shares of common stock at a weighted average price of $35.1828 per share. The filing notes that the sale prices ranged from $34.96 to $35.50 per share. These transactions were made under a Rule 10b5-1 trading plan adopted on November 27, 2024. After the transactions, Guyer directly held 1,235 shares of common stock and 250,000 stock options that are reported as fully exercisable.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Guyer William

(Last) (First) (Middle)

C/O CORCEPT THERAPEUTICS INCORPORATED

101 REDWOOD SHORES PARKWAY

(Street)

REDWOOD CITY CA 94065

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Development Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/06/2026		M		20,000	A	$21.65	21,235	D
Common Stock	01/06/2026		S(1)		20,000	D	$35.1828(2)	1,235	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$21.65	01/06/2026		M			20,000	(3)	09/01/2031	Common Stock	20,000	$0	250,000	D

Explanation of Responses:

1. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction.

2. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $34.96 to $35.50 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

3. Fully exercisable.

Remarks:

The power of attorney under which this form was signed is on file with the Commission.

	/s/ Joseph Douglas Lyon, as attorney-in-fact for William Guyer.	01/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Corcept Therapeutics (CORT) report in this Form 4?

The Form 4 reports that Chief Development Officer William Guyer exercised stock options for 20,000 shares of common stock at an exercise price of $21.65 per share and then sold 20,000 shares of common stock at a weighted average price of $35.1828 per share on January 6, 2026.

Was the Corcept Therapeutics (CORT) insider sale made under a Rule 10b5-1 trading plan?

Yes. The filing states that the share sale was made pursuant to a Rule 10b5-1 trading plan adopted by William Guyer on November 27, 2024, which was in effect at the time of the transaction.

At what prices were the Corcept Therapeutics (CORT) shares sold by the insider?

The Form 4 lists a weighted average sale price of $35.1828 per share for the 20,000 shares sold. It notes that the individual sale prices ranged from $34.96 to $35.50 per share.

How many Corcept Therapeutics (CORT) shares does the insider hold after these transactions?

Following the reported transactions, William Guyer directly held 1,235 shares of Corcept common stock. He also held 250,000 stock options that are reported as fully exercisable.

What derivative securities were involved in this Corcept Therapeutics (CORT) Form 4?

The derivative security was a stock option (right to buy) covering 20,000 shares of common stock with an exercise price of $21.65 per share. After exercising this option, 250,000 stock options remained beneficially owned directly.

What is the role of the reporting person in Corcept Therapeutics (CORT)?

The reporting person, William Guyer, is an officer of Corcept Therapeutics, serving as the company’s Chief Development Officer, and is not listed as a director or 10% owner in this filing.